Paladin Labs Inc (PLB-T) Stock Predictions - Stockchase
WATCH LIST
26
Paladin Labs Inc (PLB-T)

ON STOCKCHASE SINCE Feb 2002

pipeline for small drug companies.

Acquired by Endo (March 2014)

biotechnology/pharmaceutical

Paladin Labs Inc

PLB-T

13 watching          
Join the Discussion

Paladin Labs Inc (PLB-T) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about PLB-T



  • All
  • Filtered
Signal Opinion Expert
BUY
Paladin Labs Inc(PLB-T) 

October 18, 2013

His 3rd largest position.  A good buy at $63 mark.  Thinks they are over capitalized and could institute a dividend. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

His 3rd largest position.  A good buy at $63 mark.  Thinks they are over capitalized and could institute a dividend. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$63.650
Owned Owned
Yes

HOLD
Paladin Labs Inc(PLB-T) 

September 30, 2013

Would not sell it here.  A quarter of the market cap is in cash.  Lots of opportunity to do new deals.  Lots of growth opportunities to come.  The next catalyst could be a share buyback or large special dividend.  It’s a keeper.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Would not sell it here.  A quarter of the market cap is in cash.  Lots of opportunity to do new deals.  Lots of growth opportunities to come.  The next catalyst could be a share buyback or large special dividend.  It’s a keeper.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
James Hodgins

Chief Inve, Curvature Hedge Stra...

Price Price
$62.000
Owned Owned
Unknown

PAST TOP PICK
Paladin Labs Inc(PLB-T) 

June 24, 2013

(A Top Pick June 18/12. Up 15.18%.) Still likes. Has a massive cash position but in the last couple of weeks have announced a couple of loan deals where they are lending money to other pharmaceutical companies at a high level of interest. Have also announced some new blockbuster drugs that they are going to market in Canada and the US.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick June 18/12. Up 15.18%.) Still likes. Has a massive cash position but in the last couple of weeks have announced a couple of loan deals where they are lending money to other pharmaceutical companies at a high level of interest. Have also announced some new blockbuster drugs that they are going to market in Canada and the US.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$53.020
Owned Owned
Yes

PAST TOP PICK
Paladin Labs Inc(PLB-T) 

April 3, 2013

(A Top Pick May 7/12. Up 14.55%.) Very high ROC. Sitting on a lot of cash and keeps wondering when they are going to do something major with it. It is starting to make their ROE turn over so he, from a portfolio point of view, will have to make a decision.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick May 7/12. Up 14.55%.) Very high ROC. Sitting on a lot of cash and keeps wondering when they are going to do something major with it. It is starting to make their ROE turn over so he, from a portfolio point of view, will have to make a decision.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$48.350
Owned Owned
Yes

COMMENT
Paladin Labs Inc(PLB-T) 

February 6, 2013

Very consistent earnings. Having their annual meeting next week and he would hope that they will declare a big dividend. Generates about $80 million a year and have about $250 million of cash on their books and no debt.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Very consistent earnings. Having their annual meeting next week and he would hope that they will declare a big dividend. Generates about $80 million a year and have about $250 million of cash on their books and no debt.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$43.520
Owned Owned
Yes

PAST TOP PICK
Paladin Labs Inc(PLB-T) 

January 8, 2013

(A Top Pick Jan 13/12. Up 1.73%.) Have a massive amount of cash. Last year’s under performer but looks like it is a star in his portfolio this year.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Jan 13/12. Up 1.73%.) Have a massive amount of cash. Last year’s under performer but looks like it is a star in his portfolio this year.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$44.000
Owned Owned
Yes

PAST TOP PICK
Paladin Labs Inc(PLB-T) 

November 23, 2012

(A Top Pick Dec 12/11. Up 2.79%.) A bit of a weak quarter because of problems in South Africa. Everything is good. The problems in South Africa are just a current quarter type of thing and is part of the consolidation process. Biggest issue going forward is that they have an $850 million market cap with $250 million of cash. In terms of enterprise value to EBITDA it is trading at 6 times. Throws off a ton of excess cash flow.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Dec 12/11. Up 2.79%.) A bit of a weak quarter because of problems in South Africa. Everything is good. The problems in South Africa are just a current quarter type of thing and is part of the consolidation process. Biggest issue going forward is that they have an $850 million market cap with $250 million of cash. In terms of enterprise value to EBITDA it is trading at 6 times. Throws off a ton of excess cash flow.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$40.150
Owned Owned
Yes

COMMENT
Paladin Labs Inc(PLB-T) 

October 3, 2012

They don't have a huge exposure into any one area. We don't get a huge amount of detail on their overseas operations. His bigger issue is the cash keeps building up in this company and is starting to undermine the return on equity.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They don't have a huge exposure into any one area. We don't get a huge amount of detail on their overseas operations. His bigger issue is the cash keeps building up in this company and is starting to undermine the return on equity.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$44.300
Owned Owned
Yes

TOP PICK
Paladin Labs Inc(PLB-T) 

June 18, 2012

Great, long-term growth stock. Have $250 million in cash and the stock will continue to go up and up. Someday they're going to make a huge acquisition which will result in a huge revision of earnings. Could be a $70 stock in a year’s time.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Great, long-term growth stock. Have $250 million in cash and the stock will continue to go up and up. Someday they're going to make a huge acquisition which will result in a huge revision of earnings. Could be a $70 stock in a year’s time.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$46.120
Owned Owned
Yes

TOP PICK
Just delivered a quarter that was a beat. The real story is that they are sitting on a huge pile of cash which they are looking to deploy. When you have an $800 million company with $250 million of cash waiting to spend, impact on earnings will be significant. If you wait for announcements to come out, you are too late. Very attractive level.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Just delivered a quarter that was a beat. The real story is that they are sitting on a huge pile of cash which they are looking to deploy. When you have an $800 million company with $250 million of cash waiting to spend, impact on earnings will be significant. If you wait for announcements to come out, you are too late. Very attractive level.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$42.210
Owned Owned
Yes

BUY
Paladin Labs Inc(PLB-T) 

March 5, 2012

Growing in parts through acquisition. Thinks they are working on all kinds of stuff that will eventually show up.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Growing in parts through acquisition. Thinks they are working on all kinds of stuff that will eventually show up.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$41.760
Owned Owned
Yes

PAST TOP PICK
Paladin Labs Inc(PLB-T) 

February 3, 2012

(A Top Pick March 15/11. Up 37.07%.)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick March 15/11. Up 37.07%.)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$45.880
Owned Owned
Unknown

TOP PICK
Paladin Labs Inc(PLB-T) 

January 16, 2012

Pharmaceuticals, so very defensive earnings. Have to grow 15% annually before management gets bonuses. Long term track record is excellent. Great management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Pharmaceuticals, so very defensive earnings. Have to grow 15% annually before management gets bonuses. Long term track record is excellent. Great management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$43.050
Owned Owned
Yes

TOP PICK
Paladin Labs Inc(PLB-T) 

December 12, 2011

Outstanding value creation. Return on capital close to 40%. 200 Million cash. Can expect big acquisitions to come in the next year or two. CEO is on the mend after an accident.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Outstanding value creation. Return on capital close to 40%. 200 Million cash. Can expect big acquisitions to come in the next year or two. CEO is on the mend after an accident.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$39.450
Owned Owned
Yes

COMMENT
Paladin Labs Inc(PLB-T) 

September 8, 2011

CEO suffered a serious head injury from a motorcycle accident, which is why the stock has dropped. Fabulous company with great management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
CEO suffered a serious head injury from a motorcycle accident, which is why the stock has dropped. Fabulous company with great management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$34.290
Owned Owned
Unknown

Showing 1 to 15 of 26 entries
Successfully Saved Company
Successfully Saved Company
3+
JOIN THE DISCUSSION
3 comments in the last 7 days